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Multilocus genotypes have been shown to be of relevance for using pharmacogenomic
principles to individualize drug therapy. As it relates to thiopurine therapy, genetic polymor-
phisms of TPMT are strongly associated with the pharmacokinetics and clinical effects
of thiopurines (mercaptopurine and azathioprine), influencing their toxicity and efficacy.
We have recently demonstrated that TPMT and ITPA genotypes constitute a multilocus
genotype of pharmacogenetic relevance for children with acute lymphoblastic leukemia
(ALL) receiving thiopurine therapy. The use of high-throughput genomic analysis allows
identification of additional candidate genetic factors associated with pharmacogenetic phe-
notypes, such as TPMT enzymatic activity: PACSIN2 polymorphisms have been identified
by a genome-wide analysis, combining evaluation of polymorphisms and gene expres-
sion, as a significant determinant of TPMT activity in the HapMap CEU cell lines and the
effects of PACSIN2 on TPMT activity and mercaptopurine induced adverse effects were
confirmed in children with ALL. Combination of genetic factors of relevance for thiopurine
metabolizing enzyme activity, based on the growing understanding of their association
with drug metabolism and efficacy, is particularly promising for patients with pediatric ALL.
The knowledge basis and clinical applications for multilocus genotypes of importance for
therapy with mercaptopurine in pediatric ALL is discussed in the present review.
Keywords: acute lymphoblastic leukemia, mercaptopurine, pharmacogenetics, multilocus genotypes,TPMT, ITPA,
PACSIN2
INTRODUCTION
The principle of personalized therapy is the identification and
application of features associated with treatment response, to
select adequate medications and their doses, in order to offer
to patients the most effective treatment, with the lower inci-
dence of adverse events (Cheok and Evans, 2006). Among the
several features that can be used to personalize therapy, demo-
graphic, clinical, and pharmacological ones have been consid-
ered. The application of therapy targeted according to these
features, related to different treatment outcomes, has greatly
improved the effectiveness and safety of therapy, in particular
for patients with pediatric cancer, such as acute lymphoblastic
leukemia (ALL).
PERSONALIZED THERAPY IMPROVES TREATMENT EFFECTS:
THE PARADIGM OF CHILDHOOD ALL
Optimal use of existing antileukemic agents and improved sup-
portive care in contemporary clinical trials have improved the
5-year survival rate of childhood ALL above 85% in developed
countries, a disease that was universally fatal in the sixties; more-
over, molecular characteristics of leukemia cells have been shown
to influence treatment response (Pui and Evans, 2006; Pui et al.,
2012).
Pharmacological therapy for childhood ALL consists in pro-
tocols in which specific treatment approaches may differ but
consistently comprise three major treatment phases: remission
induction therapy followed by consolidation/intensification ther-
apy and then continuation/maintenance treatment to eliminate
residual leukemic cells (Pui and Evans, 2006). Several medica-
tions are used in these treatment phases, comprising various
lympholytic and cytotoxic drugs such glucocorticoids (i.e., pred-
nisone, dexamethasone), asparaginase and vincristine, which are
particular important for the induction of disease remission. The
purine analog mercaptopurine is a key medication for the success-
ful treatment of childhood ALL, in particular for the consolidation
and continuation therapies and is used in combination with the
folate analog methotrexate: for the success of ALL treatment, the
18–24 months of adequate maintenance therapy comprising mer-
captopurine and methotrexate have a key role and are necessary to
prolong and consolidate the remission obtained during the initial
treatment phases (Pui and Evans, 2006; Paugh et al., 2010; Stocco
et al., 2010).
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GENETIC FEATURES MAY INFLUENCE RESPONSE TO THERAPY
Genetic polymorphisms for genes involved in drug metabolism,
transport and molecular mechanism of action can alter the
concentration of active metabolites and the molecular function
of drugs’ targets and therefore the efficacy and safety of pharma-
cological therapies (Paugh et al., 2011; Pinto et al., 2012). These
genetic polymorphisms could therefore function as biomarkers
for toxicity and efficacy, allowing the identification of patients with
modified sensitivity, because of their genetic characteristics involv-
ing drug pharmacokinetics and pharmacodynamics. While many
associations between single genetic polymorphisms and drug
effects have been clearly demonstrated, showing that inherited
genomic variation causes substantial interindividual differences
in drug effects, the clinical implementation of these associations
is still limited (Relling and Klein, 2011). This is due mainly to
the lack of freely available, peer-reviewed, updatable, and detailed
gene/drug clinical practice guidelines and even to the very high
standards many clinicians and regulators hold for pharmacoge-
netic evidence (Relling et al., 2010). One of the main efforts to
provide these guidelines, which could base the clinical implemen-
tation of pharmacogenomics, is that of the Clinical Pharmaco-
genetics Implementation Consortium (CPIC; Relling and Klein,
2011). CPIC was established in 2009 and consists of members
of the Pharmacogenomics Research Network, the main US-based
research network in this field, supported by the PharmGKB staff,
one of the most important resources for curated pharmacoge-
nomics knowledge (McDonagh et al., 2011), and other affiliated
experts in pharmacogenetics, pharmacogenomics and laboratory
medicine (Relling and Klein, 2011).
Currently, the CPIC has provided guidelines for pharmaco-
genetic implementation for 7 medications: abacavir, allopuri-
nol, clopidogrel, codeine, simvastatin, thiopurines, and warfarin
(https://www.pharmgkb.org/page/cpic). The process of guidelines
definition and preparation is still ongoing and other poten-
tial guidelines may be of interest, such as inosine triphosphate
pyrophosphatase (ITPA) genetic polymorphism and ribavirin
(Fellay et al., 2010), for which a good amount of evidence and repli-
cation has been made (Ochi et al., 2010; Thompson et al., 2010;
D’Avolio et al., 2012). Moreover, besides CPIC, other research
groups have been putting together similar guidelines, such as the
European Dutch and German translational pharmacogenomics
research teams (Swen et al., 2008, 2011; Schwab and Brauch, 2012).
For the pharmacological therapy of pediatric ALL, several
examples have been reported of genetic polymorphisms influ-
encing drug response and toxicity, such as for prednisone poly-
morphisms of SMARCB1 (Pottier et al., 2007, 2008) and GST-M1
(Marino et al., 2009), for methotrexate solute carrier organic anion
transporter family member 1B1 (SLCO1B1) (Trevino et al., 2009;
Ramsey et al., 2012), for vincristine ABCB1 and CYP3A4/CYP3A5
(Paugh et al., 2010); however, the only drug – gene pair with a vali-
dated guideline published by CPIC that is fully relevant for therapy
of pediatric ALL is that of mercaptopurine and thiopurine-S-
methyltransferase (TPMT). Indeed, for mercaptopurine, genetic
polymorphisms of TPMT have been demonstrated to influence
drug metabolism and its effects, constituting one of the most
studied and significant example of associations between drug clin-
ical effects and a genetic polymorphism (Paugh et al., 2011).
In lymphoid tissues, mercaptopurine is converted to its active
metabolites, the thioguanine nucleotides (TGNs) and is inacti-
vated primarily to methylmercaptopurine by TPMT (Stocco et al.,
2010; Zaza et al., 2010). TPMT is encoded by a gene that has
non-synonymous single-nucleotide polymorphisms, leading to
reduced TPMT activity. In the majority of world populations stud-
ied to date, ∼1 in 180 to 1 in 3,700 individuals (depending on
ethnicity) inherit two non-functional variants of the TPMT gene,
3–14% are heterozygous, and the rest are homozygous wild-type.
With chronic conventional doses of mercaptopurine, patients who
inherit two inactive TPMT alleles universally experience severe
myelosuppression, because of accumulation of high levels of cel-
lular TGNs; a high proportion (30–60%) of patients heterozygous
for a TPMT variant allele does not tolerate full doses of mercap-
topurine, again because of excessive TGNs. Three TPMT single-
nucleotide polymorphisms account for more than 90% of inacti-
vating alleles and therefore genotyping tests have a high likelihood
of being informative. Characterization of TPMT deficiency by
genotyping for the most common inactivating single-nucleotide
polymorphisms can prospectively identify patients at higher risk
of mercaptopurine hematopoietic toxicity; such genotyping is
recommended in US Food and Drug Administration-approved
labeling (Paugh et al., 2010, 2011).
The diagnosis of TPMT deficiency allows the rational reduc-
tion of mercaptopurine dosages while other concurrent cytotoxic
agents remain at their usual unadjusted doses, thereby avoiding
toxicity without compromising efficacy. For patients with ALL
taking mercaptopurine, the CPIC guidelines indicate that these
subjects with the homozygous variant should start with drastically
reduced dose (i.e., reduce daily dose 10-fold and reduce frequency
to thrice weekly instead of daily) and in case of myelosuppres-
sion, emphasis should be on reducing mercaptopurine over other
agents; patients heterozygous for TPMT variant alleles (interme-
diate activity) should start at 30–70% of full dose and again, in case
of myelosuppression, emphasis should be on reducing mercaptop-
urine over other agents. Patients with normalTPMT should begin
therapy with normal starting dose and adjust doses of mercaptop-
urine (and of any other myelosuppressive therapy) without any
special emphasis on mercaptopurine compared to other agents.
For all genotypes, in case of dose adjustment, the guidelines specify
to allow 2–6 weeks to reach steady state after each dose adjust-
ment, with longer time needed for patients with inactive allele(s)
as compared to patients with functional ones (Relling et al., 2011;
Table 1). Indeed, it has been shown that, in an ALL protocol using
mercaptopurine,prospective adjustment of mercaptopurine based
on TPMT status allowed successful treatment of patients with vari-
antTPMT at a reduced dose, with toxicity and efficacy comparable
to those in patients with wild-type TPMT (Relling et al., 2006;
Stocco et al., 2009).
MULTILOCUS GENOTYPES
Most of the associations evaluated in the literature and those ready
for clinical implementation, i.e. with published curated guidelines,
are considering single gene influencing response to a particular
drug. However, one of the most important, in terms of relevance
and diffusion of drug treatment and potential improvement of
guideline application to influence drug use in the clinical setting
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are the guidelines for warfarin, the most commonly used oral
anticoagulant worldwide (Johnson et al., 2011); indeed, these
guidelines consider genetic variability at two loci: one for the
hepatic drug metabolizing enzyme CYP2C9 and one for the
target enzyme of warfarin, that is vitamin K-epoxide reduc-
tase (VKORC1). CYP2C9 and VKORC1 genetic polymorphisms
account for up to 18 and 30%, respectively, of the variance in
stable warfarin dose among patients of European ancestry: these
common polymorphisms in both genes affect warfarin phar-
macokinetics (CYP2C9) and pharmacodynamics (VKORC1) and
modulate the therapeutics dose necessary to maintain the optimal
level of drug effect (i.e., anticoagulation), preventing the risk of
adverse events due to low efficacy or excessive anticoagulation (i.e.,
respectively thrombosis or bleeding). Combination of CYP2C9
and VKORC1 genetic polymorphisms is important to select the
most appropriate dose to start therapy with warfarin: patients are
classified by the multilocus genotype in a 2× 2 table, according to
the combined effects of the most relevant polymorphisms in each
gene (two SNPs for CYP2C9 and one SNP for VKORC1) in three
levels of warfarin starting dose; this table is currently inserted
in the US Food and Drug’s Administration approved warfarin
label. More complex algorithms, comprising even relevant demo-
graphic and clinical patient’s characteristics affecting warfarin
efficacy, such as age, smoking status and interacting drugs have
been developed; some of these algorithms consider even additional
genetic information besides CYP2C9/VKORC1 multilocus geno-
type, such as polymorphisms of the CYP4F2 and GGCX genes. It
has been shown that warfarin dosing criteria considering genetics
outperform non-genetic clinical algorithms and are particularly
beneficial for patients requiring relatively low or high doses of the
medication (i.e.,<21 mg/week or>49 mg/week), that however are
∼40% of all patients: thanks to genetic based dose selection, these
patients reach their optimal dose level more quickly and therefore
with a lower risk of developing adverse events. Moreover, these cri-
teria are particularly important for patients starting warfarin ther-
apy, while are less useful for already established treatments. The
development of these important therapeutic guidelines, consid-
ering a multilocus genotype affecting warfarin dose requirements
illustrates how genetic information in more than one gene can
be of clinical relevance to guide therapy for a single medication.
Other similar guidelines considering multiple loci are in develop-
ment, such as CYP2D6 /CYP2C9 multilocus genotype for tricylic
antidepressants (Consortium, 2012).
MULTILOCUS GENOTYPES OF RELEVANCE FOR THERAPY
PERSONALIZATION OF PEDIATRIC ALL
TPMT AND ITPA AND MAINTENANCE THERAPY FOR PEDIATRIC ALL
In addition to TPMT, other genetic factors may alter the effects
of mercaptopurine, although their clinical importance has not
been as well characterized. It has been shown that once mer-
captopurine treatment for childhood ALL is individualized for
TPMT, the effect of genetic polymorphisms in inosine triphos-
phate pyrophosphatase (ITPA) emerges (Stocco et al., 2010). ITPA
is an enzyme that catalyzes the hydrolysis of inosine triphosphate
(ITP) to inosine monophosphate (IMP). IMP is a central inter-
mediate in purine metabolism and can be converted to ITP and
to ATP via AMP or to GTP via GMP. The putative role of ITPA
is to protect cells from the accumulation of potentially harmful
nucleotides, such as ITP or deoxy-ITP, which may be incorpo-
rated into nucleic acids; indeed, it has been demonstrated by
knock-down experiments performed in HeLa cells, that ITPA has
a significant role in preventing base analog induced apoptosis,
DNA damage, and mutagenesis in human cells (Menezes et al.,
2012). In humans, ITPA displays a genetically determined poly-
morphic activity (Marsh and Van Booven, 2009; Stocco et al.,
2010). Characterization of ITPA haplotype structure has shown
that the SNP rs1127354 is the most relevant polymorphism in
determining ITPA low enzymatic activity (von Ahsen et al., 2008;
Stocco et al., 2010). Our recent study assessed the influence of non-
functional variant alleles of TPMT and ITPA on mercaptopurine
metabolism and toxicity in patients with ALL whose mercaptop-
urine doses were adjusted based onTPMT genotype (Stocco et al.,
2009). This study revealed that the cumulative incidence of severe
adverse effects (grade 3–4 febrile neutropenia) in patients receiving
maintenance therapy that includes mercaptopurine individual-
ized for TPMT is significantly greater among patients who have
inherited an ITPA variant allele; this association remained signifi-
cant when the analysis was limited to only life threatening events
(i.e., grade 4 fever and neutropenia). Our recent study has doc-
umented that inheritance of a non-functional variant allele for
either TPMT or ITPA is associated with significant modification
in the metabolism of mercaptopurine during treatment of ALL.
Although the importance of the TPMT genetic polymorphism is
very well known and characterized, this was the first report show-
ing a significant effect of the ITPA genetic polymorphism in the
context of mercaptopurine therapy that has been individualized
based on TPMT genotype. We documented significantly higher
concentrations of the methylated nucleotide metabolites of mer-
captopurine in leukemia cells and erythrocytes of patients who
have inherited a non-functional ITPA allele. In contrast, the inher-
itance of a variant ITPA allele was not associated with differences
in TGN concentrations in either leukemia cells or erythrocytes.
Although ITPA is known to be involved in mercaptopurine metab-
olism, the mechanism by which ITPA variant alleles influence the
accumulation of methylated thionucleotides has not been fully
elucidated (Stocco et al., 2009, 2010).
A recent study has replicated the observation of the effects
of the combined TPMT and ITPA genotype on the mercaptop-
urine pharmacokinetics and in particular on the concentration of
methylated-mercaptopurine-nucleotides: among 66 children with
ALL, treated according to EORTC 58951 protocol, comprising
mercaptopurine at a dose of 50 mg/m2/day and methotrexate at a
dose of 20 mg/m2/week, methylated-mercaptopurine-nucleotides
concentrations were low in patients with TPMT variant/ITPA
wild-type multilocus genotype, intermediate in wild-type/wild-
type patients and high in patients with wild-type TPMT /ITPA
variant (Adam de Beaumais et al., 2010).
It is known that ethnic differences for genotype frequencies
may influence treatment efficacy in ALL: for example, it has
been reported that the component of genomic variation that co-
segregated with Native-American ancestry was associated with
risk of relapse, even after adjusting for known prognostic fac-
tors (Yang et al., 2011). The allele frequencies of TPMT and
ITPA polymorphisms show significant inter-ethnic variability: in
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particular for rs1127354 of ITPA allele frequency of the variant is
known to be∼20% in Asian populations,∼6% in Caucasians, and
∼2% in Hispanics, while for TPMT, the most common variants
(rs1142345, rs1800460 and rs1800462) have a frequency of∼1% in
Asians,∼5% in Caucasians, and∼10% in Hispanics. Therefore, it
is interesting that for TPMT and ITPA, frequencies of the variant
alleles associated with different metabolism of mercaptopurine,
seem to be almost reversal in the two populations (Marsh and Van
Booven, 2009) and ITPA variants seem to be predominant in the
Asian population. Indeed several recent studies of patients of Asian
ethnicity seem to underline significant effects of ITPA polymor-
phisms on thiopurines’ efficacy and toxicity in patients with ALL,
but even when these medications are used as immunosuppressants
in other pathologies (Okada et al., 2009; Yamamoto et al., 2010).
For children with ALL, a recent study in 90 Indian patients, on
maintenance therapy according to the MCP-841 protocol (Advani
et al., 1999) with mercaptopurine at a dose of 75 mg/m2 for
12 weeks, showed an independent role for bothTPMT and ITPA in
terms of association with the incidence of hematological toxicity;
moreover, the multilocus genotype TPMT /ITPA was associated
with a gene-dosage effect: percentage of reduction in total leuko-
cyte count (i.e., the average leukocyte count on days 43, 71, and
99 of maintenance therapy) resulted in∼40% for a patient with a
wild-type genotype at both theTPMT and ITPA loci and increased
proportionally to the number of risk alleles (i.e., variant inactive
alleles for TPMT or ITPA) up to almost 70% in patients with
three or more risk alleles at the TPMT and ITPA loci (Dorababu
et al., 2012a). Analysis of epistasis by multifactor dimensionality
reduction (Hahn et al., 2003) confirmed synergistic interactions
between TPMT and ITPA variant alleles, in terms of their associa-
tion with hematological toxicity during ALL maintenance therapy
for this cohort of Indian children. Another recent study consid-
ered 100 Korean patients with pediatric ALL and evaluated in
these patients 18 loci in 16 candidate genes of pharmacogenetic
interest, including TPMT and ITPA, and their association with
survival rate. Even if this study did not seem to confirm a strong
difference for TPMT and ITPA gene variants between a western
population of reference and the Korean patients, there was a sig-
nificant effect of ITPA genotype, but not of TPMT, on the event
free survival rate, which was lower in ITPA variants. TPMT geno-
type was however associated with the tolerance of mercaptopurine
and methotrexate, evaluated as the dose of the medications used
during the last cycle of maintenance therapy: indeed, as expected,
patients with variant TPMT were selected to be treated with lower
doses of mercaptopurine; unfortunately, data about the effect of
ITPA genotype on the doses of antimetabolites was not reported
(Kim et al., 2012).
Tanaka et al. (2012) have measured the activity of ITPA in
65 Japanese children with pediatric ALL, showing that patients
with lower activity of this enzyme tolerated lower doses of mer-
captopurine during maintenance therapy and presented increased
probability of hepatoxicity.
In Asian populations, therefore, polymorphisms of ITPA seem
to be of particular relevance for the effects of mercaptopurine
in children with ALL, given the low incidence of patients with
variant TPMT, compared to patients of Caucasian ethnicity
(Marsh and Van Booven, 2009). However, it is known that other
genetic polymorphisms may be of particular importance for Asian
patients, such as SNP rs3765534 in the transporter MRP4, that
is polymorphic only in patients of Asian ethnicity and that has
been shown to modulate thiopurines intracellular levels by regu-
lating the efflux of the thionucleotides (Krishnamurthy et al., 2008;
Stocco et al., 2010).
On these bases, to understand the pharmacogenetics and
improve treatment with thiopurines in the Asian populations,
larger prospective studies are needed, considering even multilo-
cus genotypes at loci of known relevance, such as TPMT, ITPA,
and MRP4.
MULTILOCUS GENOTYPE TPMT – SLCO1B1 – PACSIN2 AND EFFECTS
ON SEVERE MUCOSITIS DURING CONSOLIDATION THERAPY FOR
PEDIATRIC ALL
During consolidation therapy for pediatric ALL, patients are
treated with weekly 24 h infusions of high dose methotrexate, up to
5 g/m2 and daily oral mercaptopurine with doses that range from
25 to 50 mg/m2. Therapy with this association of antimetabolites
has a very important role in preventing the relapse of the dis-
ease, after remission induction; however consolidation therapy is
associated with the development of adverse effects, in particular
gastrointestinal toxicity, such as stomatitis and mucositis, which
cause major discomfort for the patient and can be severe, prevent-
ing the children from normal food intake and requiring parenteral
nutrition. To avoid adverse events related to consolidation therapy,
one of the most common approaches used in therapeutic protocols
for ALL worldwide is the administration of leucovorin, a source
of folic acid, that contrasts the cytotoxic effects of methotrexate
and its association with mercaptopurine. Most protocols for ALL
worldwide measure the concentration of methotrexate in patients’
blood at the end of each infusion and administer leucovorin if
methotrexate is then still present at significant concentrations:
for example, in the Italian AIEOP-BFM ALL 2000 protocol, leu-
covorin was administered every 6 h at a dose of 7.5 mg/m2, if
methotrexate concentration resulted higher than 0.5µmol/l at
48 h from the beginning of the infusion and until methotrexate
concentration dropped below 0.25µmol/l (Conter et al., 2010;
Schrappe et al., 2011). Consolidation therapy lasts from 2 weeks
up to 3 months depending on the treatment protocol and there-
fore the length of the therapy is too short to implement therapeutic
monitoring of mercaptopurine metabolites concentration, which
are useful when the drug is taken for at least 2 months (Lennard
and Lilleyman, 1989). Advanced protocols for treatment of ALL,
developed at St. Jude Children’s Research Hospital in Memphis,
evaluate the clearance of methotrexate during the infusion and
either adjust the speed of infusion of the drug to a target con-
centration in the subsequent course (Total XV protocol) or in the
same course (Total XVI protocol). This procedure requires a quick
and efficient turnaround of the samples for the measurement of
methotrexate concentration, which need to be analyzed in a few
hours timeframe, so that the clearance of methotrexate can be esti-
mated during the infusion, and the medication’s administration
speed can be adapted to reach the desired concentration thresh-
old (i.e., 33µM for low risk patients, 65µM for standard-high risk
patients; Pui et al., 2009). Therapeutic monitoring of methotrexate
during consolidation therapy has significantly improved patients’
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tolerance to this association treatment with antimetabolites; how-
ever, about 5% of pediatric patients still develop severe stom-
atitis/mucositis, with consequences that can be life threatening.
The study of pharmacogenetic determinants of severe gastroin-
testinal (GI) toxicity during consolidation therapy has lead to
major breakthroughs in recent years, which hopefully will lead
to even better treatment of patients with ALL, completely pre-
venting the occurrence of this major adverse event. In particular,
a recent genome-wide study analyzed 500,568 germline single-
nucleotide polymorphisms to identify how inheritance affects
methotrexate plasma disposition among 434 children with ALL
who received 3,014 courses of methotrexate at 2–5 g/m2 (Trevino
et al., 2009). This study lead to the identification of polymorphisms
in SLCO1B1, as the most significant associations (p-value< 10−9)
with methotrexate clearance, even after adjusting for age, race,
sex, and methotrexate regimen. In particular, the most significant
polymorphism was the intronic rs11045879, which is in linkage
disequilibrium with the functional SNP rs4149056; these same
polymorphisms were associated even with severe GI toxicity dur-
ing consolidation therapy, mostly severe stomatitis and mucositis.
This observation was confirmed by subsequent studies (Lopez-
Lopez et al., 2011; Ramsey et al., 2012). Therefore SLCO1B1
polymorphisms are significant determinants for the occurrence
of severe GI toxicity and in particular stomatitis/mucositis, dur-
ing consolidation therapy for pediatric ALL, by an effect on
methotrexate disposition: indeed the gene product of SLCO1B1
is a transporter which mediates the sodium-independent uptake
of organic anions such as methotrexate and may play an important
role in the clearance of bile acids and organic anions.
Another relevant study has considered the role of genetic deter-
minants of mercaptopurine toxicity during consolidation therapy,
together with SLCO1B1: this study on adverse effects considered
189 children with ALL and evaluated the association between
genetic determinants of TPMT activity in patients and the inci-
dence of severe GI toxicity. The frequency of GI toxicity (grade
3–4 mucositis) in this population was 8.5%; among these patients,
deficiency in TPMT activity predisposed to an increased incidence
of severe GI toxicity during consolidation therapy which included
methotrexate (2 g/m2/week) and mercaptopurine (75 mg/m2/day,
in all patients during consolidation therapy, regardless of TPMT
genotype). Indeed, among nine patients with a variant TPMT
allele, the frequency of GI toxicity was 33%, compared with
7.2% in patients with wild-type TPMT. As previously reported
(Trevino et al., 2009), the SLCO1B1 SNP rs11045879 was also
associated with the incidence of GI toxicity: indeed none of the
patients with the SLCO1B1 CC or CT genotype had GI toxic-
ity, whereas 11.8% of the patients with the wild-type SLCO1B1
TT genotype had this side effect. Moreover, this study identified,
through the HapMap model system, an additional determinant
of TPMT activity, the PACSIN2 gene which resulted as the high-
est correlated gene to TPMT activity, in an analysis combining
polymorphisms and expression, all measured in the 30 HapMap
CEU trios (Stocco et al., 2012). The most significant PACSIN2
SNP in the HapMap analysis for TPMT activity, rs2413739, was
also significantly associated with TPMT activity in patients with
ALL, independently from TPMT genotype: the CC genotype for
the rs2413739 SNP displayed a higher TPMT activity in compari-
son to the TT genotype. Moreover, PACSIN2 SNP rs2413739 also
had a significant association with GI toxicity during consolida-
tion therapy: the frequency of toxicity was 2.1, 9.1, and 13.2%,
respectively, for the CC, CT, and TT genotype (Stocco et al., 2012).
The effects of PACSIN2 polymorphism on the incidence of severe
mucositis during consolidation therapy for pediatric ALL were
confirmed in another cohort of patients, considering 67 cases
developing the adverse event during therapy according to the
protocol AIEOP-BFM ALL 2000, which involves four weekly infu-
sion of methotrexate at the dose of 2 g/m2 and concomitant daily
treatment with mercaptopurine at the dose of 25 mg/kg. Analysis
in the validation cohort was done by a case-control design and
each case was matched to two controls from the same protocol
based on sex, age, ALL lineage and ALL risk classification, con-
firming a significant effect of PACSIN2 SNP rs2413739 on the
incidence of severe mucositis during the consolidation therapy of
pediatric ALL (Stocco et al., 2012). Interestingly, in the discovery
cohort, the effects of TPMT, SLCO1B1 and PACSIN2 polymor-
phisms were independent from each other, both in a multivariate
logistic regression model and in a classification and regression
tree analysis and could be combined in a multilocus genotype of
potential importance to predict the incidence of severe mucositis
in children with ALL treated with consolidation therapy com-
prising the combination of methotrexate and mercaptopurine
(Figure 1).
GENOME-WIDE ANALYSIS OF SNPs ASSOCIATED TO CLINICAL
RESPONSE IN PEDIATRIC ALL: IMPLICATIONS FOR THE
PHARMACOGENETICS OF MERCAPTOPURINE
Genome-wide analysis, if adequately powered, has great poten-
tial in elucidating and understanding the genomic component
associated with interindividual differences in phenotypes, even
of pharmacogenetic interest. This has been shown to be true in
model systems like the HapMap cell lines, in which statistical
power is obtained mainly by combining genomic information at
the level of gene expression and genetic polymorphisms, with the
advantage that the phenotypes can be characterized with great
accuracy and consistency (Wheeler and Dolan, 2012). This has
led for example to the identification of PACSIN2 as a significant
determinant of TPMT activity in the cell lines, with effects repro-
ducible in patients with ALL mentioned above (Stocco et al., 2012).
However, the greatest potential of the genome-wide approach
resides really in the analysis of patients’ samples: if the study is
adequately designed and powered and the phenotypes are well
collected, this approach can provide unpredictable insights on the
phenotype of interest, potentially leading to major breakthroughs
in the understanding of the genomic basis of inter-patient vari-
ability, even of pharmacogenetic traits. Several such examples exist
in the literature: besides the already mentioned role of SLCO1B1
in the disposition of methotrexate in children with ALL (Trevino
et al., 2009), this same transporter was shown to be involved in
statins’ induced myopathy (Link et al., 2008); another example
of genome-wide studies is the discovery of a role for ITPA in
anemia induced by the anti-viral agent ribavirin (Fellay et al.,
2010).
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FIGURE 1 | Barplot reporting the percentage of patients developing severe (Grade 3-4) GI toxicity during consolidation therapy in patients with ALL
treated according to the St JudeTotal 13B protocol as a function ofTPMT rs1142345 / SLCO1B1 rs11045879 / PACSIN2 rs2413739 multilocus genotype
(Stocco et al., 2012).
While in pediatric ALL genome-wide interrogation is compli-
cated by the relative small number of patients available, St. Jude
Children’s Hospital was able to publish some genome-wide stud-
ies on leukemia pharmacogenetics, thanks to access to uniformly
treated and well characterized patients and phenotypes (Trevino
et al., 2009; Yang et al., 2009, 2012; Kawedia et al., 2011). Among
these genome-wide studies of pharmacogenetic interest, some
have generated data that could be of particular interest for the iden-
tification of multilocus genotypes of relevance for the treatment
of ALL with thiopurines. In particular, these studies considered
genetic polymorphisms associated with outcome to therapy eval-
uated as minimal residual disease (MRD) (Yang et al., 2009) or
disease relapse (Yang et al., 2012); while these very important clin-
ical phenotypes of patients with ALL are not related directly only
to mercaptopurine, the genetic features identified are related even
to disposition of antileukemic drugs and may be of relevance for
mercaptopurine effects too and should be therefore considered.
The study on MRD considered two independent cohorts of
children with newly diagnosed ALL: 318 patients in St Jude Total
Therapy protocols XIIIB and XV and 169 patients in Children’s
Oncology Group trial P9906. This study identified 102 SNPs asso-
ciated with MRD in both cohorts, including five SNP in interleukin
15 (IL15). Twenty one of these SNPs were also associated with
drug disposition (evaluated as methotrexate clearance, etoposide
clearance, or methotrexate polyglutamates concentration), gener-
ally linking greater drug exposure with MRD eradication. While
concentration of mercaptopurine metabolites was not evaluated
in this study, the effects on the disposition of methotrexate, that
is associated with mercaptopurine both during consolidation and
maintenance therapy, suggest that these SNPs may be of interest
to build multilocus genotypes useful for therapy personalization
of pediatric ALL also with mercaptopurine.
FURTHER DEVELOPMENT OF MULTILOCUS GENOTYPES: EPISTASIS
AND GENE-ENVIRONMENT INTERACTIONS
Phenotypes of pharmacogenetic interest are complex, particularly
those describing patients’ response to a medication, both in terms
of efficacy and incidence of adverse events: it is likely that different
genetic features, together with environmental factors, contribute
to the interindividual variability of these phenotypes. Indeed, it is
known that the effect of genetic polymorphisms is stronger when
it refers to a pharmacokinetic phenotype and strength of the asso-
ciation reduces with the increasing complexity of the phenotype:
for example, the effect of TPMT genotype is extremely strong on
TPMT activity and the strength of the association is reduced, while
still significant, considering more complex phenotypes such as
the concentration of mercaptopurine metabolites and, even more,
considering parameters of clinical response to the medication:
the thinning of the association strength is due to the increasing
complexity of the phenotype and the augmented potential role
of environmental and additional genetic factors (Relling et al.,
2011). Moreover, for complex phenotypes such as the response
to a medication, the effects of a genetic factor may depend on
other genetic variations and environmental factors, a phenome-
non that is defined respectively as gene-gene interaction/epistastis
or as gene-environment interaction (Moore and Williams, 2009).
Methods have been developed to study consistently and efficiently
the role of multiple genetic and environmental factors on complex
phenotypes defined by discrete traits, such as those of phar-
macogenetic interest (e.g., clinical response to a medication or
occurrence of adverse events; Hahn et al., 2003; Gilbert-Diamond
and Moore, 2011). This method is called multifactor dimension-
ality reduction (MDR) and allows collapsing multi-dimensional
genetic information into a single dimension, thus permitting the
detection of epistasis: MDR is a non-parametric method and
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interactions are detected by a constructive induction approach,
in particular by classifying multiple loci as high risk or low risk,
depending on whether they are more common in affected or in
unaffected subjects; this pooling allows reducing the dimension-
ality of the multilocus data to one dimension (Hahn et al., 2003).
The new multilocus genotype variable is then evaluated for its
ability to classify and predict the phenotype of interest (i.e., drug
response): different approaches have been used to perform these
computations; originally, however, it was done by cross-validation
and permutation testing and recently extensions and variations
of the method have been developed, which allow the calculation
of odds ratios and application of Fisher’s test to increase model
robustness (Moore and Williams, 2009). Interestingly, it has been
reported that MDR allows the identification of significant gene–
gene interaction in the absence of a statistically significant main
effect by a single genotype; moreover, it was mathematically proved
that MDR is the best method to discriminate multilocus geno-
types for clinical endpoints. MDR has been successfully applied
to detecting gene–gene and gene–environment interactions for a
wide variety of different complex phenotypes, such as incidence
of human diseases and other clinical endpoints (Gilbert-Diamond
and Moore, 2011). Recently this method has been applied even for
studies of pharmacogenomics for thiopurines and methotrexate
(Dervieux et al., 2012; Dorababu et al., 2012a,b; Kim et al., 2012),
even if its application to this field is still limited and there is great
potential for discovery, in particular to detect and elucidate multi-
locus genotypes associated with genome-wide studies of complex
pharmacogenetic phenotypes.
CONCLUSION
Consideration of genetic biomarkers can improve therapy of pedi-
atric ALL: the role of TPMT genetic polymorphism on mercap-
topurine induced toxicity in children with ALL has been clearly
defined and clinical guidelines have been developed to tailor treat-
ment with this medication on the basis of TPMT status. Multilocus
genotypes have been shown to be able to increase the amount
of interindividual variability in a phenotype of clinical relevance
explained: for example, the incidence of severe GI toxicity during
consolidation therapy has been shown recently to be indepen-
dently related toTPMT,SLCO1B1, andPACSIN2 genetic polymor-
phisms. Identification, proper testing, and validation of multilocus
genotypes hold great potential in further refining the clinical util-
ity of pharmacogenetics to improve treatment of children with
ALL by reducing treatment-related adverse events.
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